Apixaban Had Lower Risk of GI Bleed than Other Oral Anticoagulants in Patients with Atrial Fibrillation

Hamidi, Arzo PharmD, BCCP

Clinical Pharmacy Specialist, Adult Critical Care, Rush University Medical Center, Chicago

Critical Care Alert 30(11):p 85-86, February 2023.

SYNOPSIS: In this multinational, population-based cohort study among patients with atrial fibrillation, apixaban use was associated with lower risk of gastrointestinal bleeding with similar rates of ischemic stroke or systemic embolism, intracranial hemorrhage, and all-cause mortality.

SOURCE: Lau WCY, Torre CO, Man KKC, et al. Comparative effectiveness and safety between apixaban, dabigatran, edoxaban, and rivaroxaban among patients with atrial fibrillation: A multinational population-based cohort study. Ann Intern Med 2022;175:1515-1524.